MoonLake Immunotherapeutics (MLTX) Other financing activities (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Other financing activities of $170000.0 for Q1 2026, down 99.76% quarter-over-quarter from $71.9 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Other financing activities (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $170000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $170000.0; the TTM figure through Mar 2026 stood at $72.6 million (up 37.87% YoY), while the FY2025 annual figure was $72.4 million, up 37.79% from the prior year.
- Other financing activities for Q1 2026 stood at $170000.0, down from $71.9 million in the prior quarter.
- The five-year high for Other financing activities was $482.5 million in Q4 2023, with the low at -$3791.0 in Q2 2022.
- The 5-year median for Other financing activities is $170000.0 (2026), against an average of $67.5 million.
- The sharpest annual moves came in 2024 and 2025: Other financing activities plunged 89.11% in 2024, then jumped 316.22% in 2025.
- MoonLake Immunotherapeutics' Other financing activities stood at -$3791.0 in 2022, then soared by 12726399.13% to $482.5 million in 2023, then slumped by 89.11% to $52.5 million in 2024, then jumped by 36.88% to $71.9 million in 2025, then slumped by 99.76% to $170000.0 in 2026.
- Business Quant data shows MLTX's Other financing activities at $170000.0 in Q1 2026, $71.9 million in Q4 2025, and $380000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 551,000.00 |
| Jun 30, 2026 | 551,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 71.92 Mn |
| Dec 31, 2025 | 71.92 Mn |
| Sep 30, 2025 | 380,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Dec 31, 2024 | 52.54 Mn |
| Dec 31, 2024 | 52.54 Mn |
| Sep 30, 2024 | 91,298.00 |
| Sep 30, 2024 | 91,298.00 |
| Dec 31, 2023 | 482.45 Mn |
| Dec 31, 2023 | 482.45 Mn |
| Jun 30, 2022 | -3,791.00 |
| Jun 30, 2022 | -3,791.00 |
| Mar 31, 2022 | 3,791.00 |
| Mar 31, 2022 | 3,791.00 |